tbuckley/cabot-search huggingface dataset:
Quantitative image analysis of cytokeratin filament distribution during fetal rat liver development
Authors: J VASSY
Journal: Hepatology (1996)

Recent reports suggest that not only chemical but also mechanical influences from the cellular environment could have profound effects on gene activity and could act on cell differentiation and proliferation. These mechanisms involve a tissue matrix system, which includes extracellular matrix, nuclear matrix, and cytoskeleton. Supposing that the cytoskeleton mediates mechanical transduction from the cell environment to the nucleus, significant differences in the spatial distribution of the cytoskeleton network could reflect variations in environmental signals. Hepatocytes during fetal development provide a useful model to study such variations, because a progressive establishment of intercellular contact is reported. The aim of this work is to discriminate steps in hepatocyte differentiation from fetal to adult livers, using computerized quantitative image analysis of cytokeratin (C8) immunofluorescent localization, visualized by confocal scanning laser microscopy. The filament structure is represented by the gray-scale skeleton of the digital images obtained by specially designed segmentation methods. A set of line features was investigated, including number and length of lines, orientation of lines, and the fractal dimension of the filament network. The features studied showed highly significant differences throughout liver development, with an increase of the total amount of cytokeratin filaments. We could also demonstrate a modification in the structure of the network, being more and more dense, with an increase of connecting points. Moreover, it has been shown that filaments have some orientation in fetal hepatocytes, and that directionality. Thus, significant differences in the pattern of the cytokeratin filament network according to the stages of hepatocyte differentiation have been demonstrated with objective and quantitative methods.
X-Linked Lymphoprollferatlve Syndrome Registry
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article X-Linked Lymphoprollferatlve Syndrome Registry Get access JNCI: Journal of the National Cancer Institute, Volume 62, Issue 3, March 1979, Page 711, https://doi.org/10.1093/jnci/62.3.711-a Published: 01 March 1979
THE PHYSICIAN'S RESPONSIBILITY IN PREVENTIVE MEDICINE
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is there a link between psoriasis and dementia?
Journal: British Journal of Dermatology (2021)

Psoriasis and dementia are both common conditions. Because of how both diseases develop within the body, they might have certain shared traits, and it has been suggested that patients with psoriasis may be at greater risk of developing impaired mental function and/or dementia. This study from Taiwan examines the published research to see whether there may be evidence of such a link.
Declining autopsy rates and diagnosis of myocardial infarction
Authors: L. K. Altman
Journal: JAMA (1984)

<h3>In Reply.—</h3> Regarding the concerns voiced by the letters of Dr Huiras and by Ina Van Hest and Dr Zoraster, we agree that the percentages are misleading and only the zero-zero figures should have been used. In regard to the letter by Dr Beach Conger, our purpose was to demonstrate the tendency of physicians to rely on technical aids for the diagnosis of myocardial infarction and their reluctance to make such a diagnosis in the absence of laboratory substantiation regardless of whether such lack of substantiation was due to (1) insufficient enzymes to evaluate, (2) enzymes that did not reach twice normal values, or (3) cases in which there was no change in enzyme values. The same philosophy would seem to apply to all three circumstances, namely, without laboratory confirmation, regardless of cause, there is physician reluctance to make a diagnosis of acute myocardial infarction. As mentioned in the article,
Clinical and in vitro evaluation of cephalexin. A new orally administered cephalosporin antibiotic
Authors: M. E. Levison
Journal: JAMA (1969)

Cephalexin was evaluated in vitro and in the treatment of urinary tract infection. The drug was absorbed well and excreted in the urine in high concentrations. Urine levels of cephalexin were adequate to inhibit more than 90% of<i>Escherichia coli, Proteus mirabilis</i>, and<i>Klebsiella pneumoniae</i>strains. Twenty-three patients with urinary tract infection were treated with cephalexin for two to three weeks. Most of the patients had evidence of structural abnormalities or chronic infection of the urinary tract. Ten patients (43%) were abacteriuric two or more months after discontinuation of therapy. Diarrhea and eosinophilia were the only side effects noted and occurred in only two patients.
Hepatitis A.
Authors: A J Tilzey, J E Banatvala
Journal: BMJ (1991)

picture.Azacitidine has been dropped from clinical use, but a preliminary report of treatment with hydroxyurea is promising.In three patients there was a 2-3-fold to 16-fold increase in the percentage of haemoglobin F and a virtual cessation ofpainful crises.9The results ofthe careful controlled study of hydroxyurea being undertaken for the National Institutes of Health are awaited with interest, although the way hydroxyurea raises the haemoglobin F concentration is still incompletely understood.Bone marrow transplantation for sickle cell disease has now been performed in a few centres, mainly in Belgium.'°Though transplantation is curative, it raises ethical issues that have yet to be fully discussed by either health professionals or patients in Britain.We need to explore these, as for I thalassaemia major.There is an urgent need in Britain to develop a structure for developing coordinated trials of new treatments for sickle cell disease.As a model haematologists have the excellently run trials for the leukaemias sponsored by the Medical Research Council.These not only produced valuable scientific infor- mation but also enabled physicians with only a few patients under their care to use up to date treatments.
HEBERDEN, CLASSICAL MEDICAL SCHOLAR
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Progress of Cholera in France.—The chances
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abdominal Surgery
Authors: Claude E. Welch
Journal: New England Journal of Medicine (1973)

SINCE the last biennial report on this subject major contributions include the development of a unified radiologic concept of the control of gastrointestinal hemorrhage, further application of physiologic concepts in the treatment of diseases of the stomach, and the development of coloscopy.1 Abdominal surgery and gastroenterology are developing a recognition of their common interests; consequently, concentration on immediate mortality and morbidity has given way to more frequent studies of late results after operative procedures.Lower EsophagusHiatus Hernia and EsophagitisA gradual change of emphasis has become apparent. As Ingelfinger has stated, the presence or absence of esophageal reflux has . . .
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Authors: Johanna C. Bendell, Alexander Starodub, Xi Huang, Julia D. Maltzman, Zev A. Wainberg, Manish A. Shah
Journal: Journal of Clinical Oncology (2017)

TPS4139 Background: GS-5745 is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. Inhibiting MMP9 blocks paracrine signaling and metastasis and alters the tumor immune microenvironment. GS-5745 (800 mg q 2 weeks) with mFOLFOX6 was examined in a Phase 1b study in 40 patients with gastric and GEJ adenocarcinoma (GS-US-296-0101), and demonstrated encouraging activity without added toxicity (10% CR, median PFS 10.7 mo (Shah et al ASCO GI 2017, a108)). Decreased free MMP9 suggested inhibition of MMP9 enzymatic activity by GS-5745. These data support the hypothesis that GS-5745 treatment inhibits MMP9 activity and that the inhibition may lead to improved clinical outcomes. Methods: This phase 3, randomized, double-blind, multicenter study investigates the efficacy and safety of GS-5745 combined with mFOLFOX6 in subjects with untreated gastric and GEJ adenocarcinoma. Total of 430 eligible subjects with advanced gastric and GEJ cancer will be randomized in a 1:1 manner to mFOLFOX6 plus GS-5745 or mFOLFOX6 plus placebo. Stratification factors include ECOG status (0 v 1), geographic region (Latin America v All other countries), and primary tumor site (gastric v GEJ). CT or MRI scans will be performed every 8 weeks to evaluate response to treatment. mFOLFOX6 will be administered on Days 1 and 15 of each 28-day treatment cycle for a total of 6 cycles followed thereafter by leucovorin (LV) and 5-fluorouracil (5-FU) dosing on Days 1 and 15 of each 28-day treatment cycle until disease progression. GS-5745/placebo 800 mg will be infused on Days 1 and Day 15 of each 28 day cycle until disease progression. Primary endpoint is OS, and secondary endpoints include PFS, ORR (RECIST 1.1), and safety. The study is designed to have an 85% power to detect clinically meaningful improvement in overall survival at the one-sided significance level of 0.025. The association of exploratory biomarkers with study drug response will also be evaluated. Enrollment opened Oct. 2015. Clinical trial information: NCT02545504.
SYNTHETIC DRUGS
Authors: JULIUS STIEGLITZ
Journal: JAMA (1918)

The work of the Federal Trade Commission in cooperation with the Committee on Synthetic Drugs of the National Research Council in providing for the manufacture in this country of the important synthetic drugs which before the war were imported from abroad, and especially from Germany, has now passed through its first stage of development. Although supplies in some articles will not be overplentiful for some weeks yet, and plans for the manufacture of some important drugs, such as phenylbarbital (luminal) are still in the stage of preparative study only, the situation has defined itself so far that its further successful development can best be attained by the frank and hearty cooperation of the medical profession with the Federal Trade Commission and the National Research Council. The purpose of this series of short articles is to insure such cooperation, first by giving specific information to physicians, second, by requesting in return
Presentation of Plate to Dr. Evory Kennedy
Journal: BMJ (1841)

infltation should then be mnade quicker, and as the attempts to breathe increase, sal volatile, or brandy, rubbed ou thie palm of the hand and held over the mouth during the in- spiration of air, will materially assist the recovery, and has a better eflTect than pouring stimulants into the stomach.A tew smart slaps on the glitteal muscles will now generally complete the recovery.It has always been my practice to respire as completely, and immediately to inhale as much air as possible, and this should be repeated frequently during the process of inflating the luings.
LIABILITY FOR PROMISE TO CURE.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxoplasmosis in the Adult
Authors: Jack S. Remington, Leon Jacobs, Herbert E. Kaufman
Journal: New England Journal of Medicine (1960)

Laboratory DiagnosisRoutine White-cell count. This ranges from leukopenia, or leukemoid reaction, to a picture of acute lymphatic leukemia. In mild cases it may be normal. Cells have been found on peripheral blood smears that could not be differentiated from the atypical lymphocytes seen in infectious mononucleosis and hepatitis. Red-cell count. Anemia may be present. Urine. The only abnormal finding may be protein-uria. Hyaline casts and red and white blood cells have been seen in the sediment in some cases. Cerebrospinal fluid. There may be increased protein and slightly lowered sugar, with pleocytosis. Liver-function studies. These may give abnormal results. . . .
Activation of coagulation factor VII by tissue‐type plasminogen activator
Authors: Hiroshi Tsujioka, Akira Suehiro, Eizo Kakishita
Journal: American Journal of Hematology (1999)

To investigate the effect of tissue-type plasminogen activator (t-PA) on blood coagulation, we examined the effects of the addition of t-PA to normal pool plasma (NPP) on clotting times such as diluted prothrombin time (PT) and kaolin clotting time (KCT). The diluted PT but not the KCT was significantly shortened by the addition of t-PA to NPP compared with the normal controls, suggesting a t-PA–induced activation of blood coagulation through factor VII (FVII) activation. The activated factor VII (FVIIa) concentration in the NPP was significantly increased by the addition of t-PA. Although the FVIIa formation was not observed following the incubation of purified FVII with only t-PA or plasminogen, an increase in the FVIIa level was observed after the incubation of purified FVII with t-PA together with plasminogen, or only plasmin. This plasmin-mediated FVIIa formation was also confirmed by Western blotting. These findings suggest that t-PA enhances the activation of the coagulation system through FVII activation. Am. J. Hematol. 61:34–39, 1999. © 1999 Wiley-Liss, Inc.
Rheumatological Medicine
Authors: George E. Ehrlich
Journal: JAMA (1986)

This rheumatologic textbook, by only four authors working together, is designed for the resident or fellow preparing for board examinations and for the physician who wants a comprehensive textbook that is not as detailed, heavy, or expensive as the major tomes recently published (by Kelley et al and McCarty). The authors admit that a spate of recent publications has said probably all that can be said at the moment about these rheumatic diseases, whose importance grows daily, especially because they are a leading source of disability and because of the controversies over medical coverage under diagnosis related groups. The book succeeds in its mission, and provides—in workmanlike style, on large pages with large type and a good deal of white space—an overview of current knowledge. The spelling is British, which should not put one off. However, "tempro-mandibular" is a misspelling, not an English spelling. The chapters on immunopathogenic mechanisms, connective-tissue
Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group
Authors: Lionel Ades, Emmanuel Raffoux, Olivier Spertini, Agnès Guerci, Christian Recher, Denis Guyotat, Eric Deconinck, Thierry Lamy De La Chapelle, Xavier Thomas, Dominique Bordessoule, Norbert Vey, Stephane de Botton, Arnaud Pigneux, Denis Caillot, Jean-Yves Cahn, Patrice Chevallier, Jean-Francois Lambert, Claude Gardin, Herve Dombret, Julie Lejeune, Sylvie Chevret, Pierre Fenaux
Journal: Blood (2016)
Frankfurter Zeitschrift Pathol, Munich
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RARE-29. PROGRAMMED DEATH LIGAND 1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES IN TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1 AND 2
Authors: Shiyang Wang, Benjamin Liechty, Seema Patel, Jeffrey Weber, Travis Hollman, Matija Snuderl, Matthias Karajannis
Journal: Neuro-Oncology (2017)

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) or its ligand (PD-L1) have been shown to be effective in treating patients with a variety of cancers. Positive associations between clinical response rates and PD-L1 expression on tumor and immune cells, as well as the presence of tumor infiltrating lymphocytes (TILs) have been found in multiple studies. It is currently unknown whether tumors associated with neurofibromatosis types 1 and 2 (NF1 and NF2) express PD-L1. We hypothesized that NF-associated tumors express PD-L1 and therefore might be amenable to immunotherapy with immune checkpoint inhibitors. We performed immunohistochemistry for PD-L1 (Spring Bioscience, clone SP142 and Cell Signaling Technology, clone E1L3N), CD3, CD20, CD8, and CD68 in 17 NF1-related tumors (11 dermal neurofibromas and 6 plexiform neurofibromas) and 20 NF2-related tumors (10 meningiomas and 10 schwannomas) using archival formalin-fixed paraffin-embedded tissues. Expression of PD-L1 was considered positive in cases with >5% membranous staining of tumor cells, in accordance with previously published biomarker studies. PD-L1 positive tumor cells with >5% membranous staining using clone SP142 or E1L3N were observed in 100% of plexiform neurofibromas, 82% and 58% of dermal neurofibromas, 70% and 100% of schwannomas, and 40% and 20% of meningiomas, respectively. Sparse to moderate presence of CD68, CD3, or CD8 positive tumor-infiltrating lymphocytes (TILs) was found in 37/37 (100%) of tumor specimens. However, expression of CD20 positive lymphocytes was limited to rare cells detectable in 4/37 (11%) of tumors. Our findings indicate that adaptive resistance to cell-mediated immunity plays a major role in the tumor immune environment of NF1 and NF2-associated tumors. Expression of PD-L1 on tumor cells and presence of TILs suggests that these tumors may be responsive to immune therapy with immune checkpoint inhibitors, which should be explored in clinical trials for NF patients.